explore -WSS

explore

author：focus 2025-10-02 08:53:28 Page View：4722

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Microsoft's Peter Lee: Generative AI could help doctors be more human
Next article： Wildfire smoke exposes gaps in outdoor worker protections

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

NIH launches clinical trials and new research office for long Covid

TheonlytrialunderwayrightnowwilltestwhetheralongerregimenofPfizer’santiviralPaxlovidalleviatessympto

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Florida health officials providing scant details on measles cases

WithfewdetailsavailableaboutmeaslescasesinFlorida,peopleconsidering vacationstothestatewhowanttoavoi